Along this line, a common polymorphism lacking the BIM-BH3-domain reduces therapeutic responses to both TKIs in CML and EGFR-inhibition in NSCLC [23]. This evidence concerns the gene BCL2L11 and chronic myelogenous leukemia, BCR-ABL1 positive.